Status:
COMPLETED
A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants
Lead Sponsor:
Eisai Korea Inc.
Conditions:
Liver Neoplasms
Carcinoma, Hepatocellular
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to describe the following safety and the efficacy of Lenvima for the first-line treatment indication of participants with uHHC in the post marketing setting: (1) Serious a...
Eligibility Criteria
Inclusion
- Participants over 18 years
- Participants who are treated with lenvatinib according to the approved indication of uHCC as first-line therapy in Korea
- Participants who have given their consent to study participation about the use of the personal data and medical data
Exclusion
- Participants who have hypersensitivity to active pharmaceutical ingredients or excipient of the study drug (lenvatinib)
- Participants who are pregnant or breastfeeding.
Key Trial Info
Start Date :
May 28 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
658 Patients enrolled
Trial Details
Trial ID
NCT05225207
Start Date
May 28 2019
End Date
January 31 2022
Last Update
January 9 2023
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Site #32
Cheonan, Chungcheongnam-do, South Korea
2
Site #35
Bucheon-si, Gyeonggi-do, South Korea
3
Site #38
Bucheon-si, Gyeonggi-do, South Korea
4
Site #06
Goyang-si, Gyeonggi-do, South Korea